WELCOME CSE: PREV OTCQB: PRVCF - Richmond Club
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
CSE: PREV
OTCQB: PRVCF
WELCOME
CSE: PREV
WHO WE ARE
OTCQB: PRVCF
Head quartered in Vancouver, British Columbia, PreveCeutical Medical Inc. is a
preventive health sciences company that develops leading-edge options for
curative and preventive therapies. The company is led by an experienced team
of senior executives and scientists with a passion for researching and developing
innovative solutions for unmet clinical needs.
The company is staking out important positions in diverse areas such as
diabetes and obesity, pain management, neurological disorders and cancer and
building an innovative IP portfolio for licensing and strategic partnerships.
PreveCeutical believes the medical community is transitioning from a system
that often only manages symptoms to one of personalized, preventive-based
treatments. With this focus, PreveCeutical is committed to becoming a leader in
preventive health sciences.
CSE: PREV
WHO WE ARE
OTCQB: PRVCF
MISSION STATEMENT
To improve global health and healthcare by utilizing innovative science and
cutting-edge technology to enhance natural products.
VISION
To be a trusted leader in providing preventive and therapeutic health
solutions that contribute to lasting health and well-being.
PHILOSOPHY
• Conduct business with honesty and integrity in an innovative and open
environment.
• Model high-quality governance, leadership and management
• Make available the best and trusted health and wellness solutions.CSE: PREV
RECENT ACHIEVEMENTS
OTCQB: PRVCF
Our cannabinoid-based Sol-gel program approval for the use of human
tissue in the final phase, unique in pre-clinical development – likely to lead
to fast-tracking through to clinical trials allowing us to work on proof of
concept.
Positive developments in our Diabetes and Obesity ‘Dual Gene Program.’
Our research team has finalized 4 (possibly more) highly potent, and novel,
Silencing RNA (siRNA) candidates each of which silence the target gene and
protein in mice AND human-derived cells by more than 80%. The unique
sequences of siRNA are PreveCeutical’s IP.CSE: PREV
CURRENT PROGRAMS
OTCQB: PRVCF
PreveCeutical has partnered with the University of Queensland for research
and development. Agreements in place give PreveCeutical ownership over
program outcomes - IP and results.
Sol-gel platform for nose-to-brain delivery of medical cannabinoids.
Nature Identical ™ (synthetic) peptides to assist with treatment of
aggressive (brain) cancers and a range of ailments.
Non-addictive, analgesic peptides to substitute dependence-
associated opioids.
Dual gene therapy for the treatment/prevention of type 2
diabetes and obesity.CSE: PREV
DEVELOPMENT PIPLINE
OTCQB: PRVCF
IND
Development Pipeline Opportunity Lead Pre-clinical
Discovery Clinical Trials Registration
Analysis Optimization Studies Ph. II Ph. IIa Ph. IIb Ph. III
POC
Sol-gel Complete ongoing Out-license/partner
Nature Identical™ Complete ongoing Out-license/partner
Non-addictive Analgesics Complete ongoing Out-license/partner
Dual Gene Therapy Complete ongoing Out-license/partner
• PreveCeutical has the use of UQ’s Linker Technology, which enables us to stabilize peptides as we are making them!
Effectively one-pot synthesis – does not require post synthesizing modalities. Faster and less labour intensive.CSE: PREV
OTCQB: PRVCF
SOL-GELCSE: PREV
SOL-GEL
OTCQB: PRVCF
Developing the first, sustained-release, Cannabis and CBD-based, nose-to-brain
delivery system that will provide relief across a range of indications from pain,
seizures, and neurological disorders.
▪ Proprietary formulation - delivery via a custom nasal spray device.
▪ Bypasses first pass metabolism - dramatically increasing bioavailability, even
compared to conventional delivery mechanisms.
▪ Universally-patient friendly, water soluble, alcohol free safe for use in adults,
children and people with alcohol-based restrictions.CSE: PREV
SOL-GEL
OTCQB: PRVCF
PreveCeutical’s research team at the University of Queensland has been
granted the necessary approvals from a local hospital’s Human Ethics
Committee for the use of human nasal mucosal tissue.
This is unique in pre-clinical development – likely to lead to fast-tracking
through to clinical trials allowing the company to work on ‘proof of concept’.CSE: PREV
SOL-GEL
OTCQB: PRVCF
PreveCeutical has fingerprinted five cannabis strains.
“Sol-gel technology has certainly shown significant promise in laboratory testing at
this point. Eventually, I would like to see this proprietary technology be successfully
applied to a drug which could be targeted for CNS delivery. At the right time, we
would welcome an opportunity to work with a pharmaceutical or biotechnology
company to co-develop the Sol-gel and Sol-gel Applicator to be used in
pharmaceutical and therapeutic products.”
– PreveCeutical’s President & Chief Science Officer, Dr. Mak Jawadekar.CSE: PREV
OTCQB: PRVCF
DUAL GENE THERAPYCSE: PREV
DUAL GENE THERAPY
OTCQB: PRVCF
The American Diabetes Association estimated in 2018 there were more than 500
million prevalent cases of type 2 diabetes worldwide.1
According to the Institute of Health Metrics and Evaluation, about 30% of the
global population is either obese or overweight.2
• Kills one person every six seconds
• 2015 global expenditure $673 Bn USD and 2040 projections $802 Bn USD3
• Losses in GDP worldwide from 2011-2030 $1.7 Trillion USD4
1https://diabetes.diabetesjournals.org/content/67/Supplement_1/202-LB, 2https://www.grandviewresearch.com/press-release/global-obesity-treatment-
market, 3http://www.diabetesatlas.org/, 4http://apps.who.int/iris/bitstream/10665/204871/1/9789241565257_eng.pdfCSE: PREV
DUAL GENE THERAPY
OTCQB: PRVCF
PreveCeutical is working with three leading Australian research centres to
co-develop a curative therapy for type 2 diabetes and obesity.
Our research team has finalized 4 (possibly more) highly potent, and novel
Silencing RNA (siRNA) candidates each of which silence the target gene and
protein in mice and human-derived cells by more than 80%. The unique
sequences of siRNA are PreveCeutical’s IP.CSE: PREV
OTCQB: PRVCF
KEY EXPERTISECSE: PREV
KEY EXPERTISE
OTCQB: PRVCF
Steven Van Deventer – Chairman and CEO
Twenty five years specializing in international corporate relations and business development.
Spearheaded the financing and RTO for Aurora Cannabis, now trading on the NYSE, and also helped
raise the financing for Hempco.
Dr. Mak Jawadekar – President and Chief Science Officer
A 28-year Pfizer executive and Director of Portfolio management and part of the team that
developed and brought Zoloft to market, one of the worlds most prescribed anti-depressants.
Shabira Rajan – Chief Financial Officer and Controller
The financial expertise that brought the Canada Line, a $2billion expansion line for the rapid transit
systems serving Metro Vancouver, on time and under budget.
Dr. Harry Parekh – Chief Research Officer
Heads the Drug/Gene Delivery Group at PACE-UQ, the university that brought the world Gardasil,
the cervical cancer vaccine. Also holds adjunct positions at the National university of Singapore, and
Manipal University India.CSE: PREV
ADVISORY BOARD
OTCQB: PRVCF
Nicole Goncalves-Krysinski Nicole Goncalves-Krysinski, Esq., is an attorney and a partner in her own law firm in New York City, New
Foreign Legal Advisor York. She has a J.D. from St. John’s University and B.A. from U.C.L.A. Nicole practices in both state and
federal courts handling a wide range of cases including complex bankruptcy matters, matrimonial and
criminal defense litigation. Her areas of practice also include contract negotiations, business and
transactional law and corporate advisement.
Isaac Moss Isaac Moss B.Sc., M.Pub.Admin. has 30 years of experience in international corporate finance, public
markets and business. Isaac was associated with an advisory group in Geneva Switzerland, providing
strategic and corporate finance advisory services to a number of client companies around the globe in
diverse industries ranging from mining and energy, forest products, technology, telecommunications and
bio-technology, and the hospitality industry.
Ian has been a serial entrepreneur from his mid 20's having worked in the finance industry working as a
Ian Spencer commodity broker in central London. Ian studied Business and Finance Law at Brunel University, London, but
chose commercial trading as his passion was for dealing art and antiques which he was extremely successful
at.
The founder and Director of Concord Business Development, Wanda Halpert is a veteran in the strategic
Wanda Halpert planning industry. She has delivered presentations on the essentials of business planning to public company
forums and federally funded management programs and directed the productions of over 500 advanced
business plans in dozens of industry sectors for both private and public companies.CSE: PREV
SHARE STRUCTURE
OTCQB: PRVCF
As of June 24th, 2019.
Common shares issued and outstanding: 398,448,905
Updated: 2019-06-04 – 13:14:23 | Symbol: PREV.CN
Open: 0.050 Volume: 15000
Last: 0.050 Day Hi: 0.050
Change: 0.00 Day Low: 0.050CSE: PREV
WHY INVEST?
OTCQB: PRVCF
✓ Our Sol-gel is niche; no one else is coating the olfactory region, and we have successfully
fingerprinted five cannabis strains.
✓ Our world-class team has the expertise to bring these projects to market.
✓ Drug approvals are now faster, the customer/patient base is steadily increasing and many rising
sectors, now is a good time to invest in pharma, in particular, smaller companies with substantial
growth potential like PreveCeutical.CSE: PREV
OTCQB: PRVCF THANK YOU
Please contact:
Deanna Kress
Director of Corporate Communications & Investor Relations
Cell: 1 (778) 999-6063
Office: 1 (604) 416-7777 ext. 6288
deanna@preveceutical.comCSE: PREV
TEAM
OTCQB: PRVCF
Stephen Van Deventer - Chairman and Chief Executive Officer
Appendix Mr. Van Deventer is an experienced businessman and corporate director. Specializing in international corporate
relations and business development over the last twenty-five years, Mr. Van Deventer has focused on launching small
to medium-sized companies into the public markets in Canada, the United States and Europe. He has also owned
and operated private companies.
Mak Jawadekar PhD – President, Chief Science Officer and Director
Dr. Jawadekar completed his Ph.D. in Pharmaceutics at the University of Minnesota. Dr. Jawadekar worked at
Pfizer Inc. for twenty-eight years, where he most recently acted as the Director of Portfolio Management. During
his career, he was responsible for drug delivery technology assessments involving external drug delivery
technologies. Dr. Jawadekar has extensive experience in creating and cultivating external partnerships and
alliances for drug delivery technologies.
Matt Coltura -Director
Mr. Coultura is in the final year of the BBA, with a finance option, at the Okanagan College. He is experienced in business
and finance. He is the CFO of Cayenne Capital Corp. and, in addition to PreveCeutical, he sits on the board of directors for
Stoneridge Exploration Corp. and Cayenne Capital Corp.CSE: PREV
TEAM
OTCQB: PRVCF
Shabira Rajan, MBA, CPA, CGA - Chief Financial Officer
Appendix Ms. Rajan is a senior financial executive with over 20 years of experience, leading the financial discipline for successful
businesses in both private and public sectors. She has a track record of providing leadership for strategic value creation
and continuous improvement, as well as, providing effective direction to organizations on issues relating to corporate
governance, financial oversight and risk management. One of her leadership roles was that of Director of Finance at
Canada Line Rapid Transit Inc., which planned and constructed a $2 billion rapid transit system in metro-Vancouver, on
time and within budget.
Harry Parekh PhD, BSc HonsI - Chief ResearchOfficer
Based at the University of Queensland’s (UQ) Pharmacy Australia Centre of Excellence (PACE), Dr. Parekh also holds adjunct
positions at the National University of Singapore, and Manipal University,India.
Dr. Parekh heads the Drug/Gene Delivery Group at PACE-UQ with his team developing highly innovative and translational
medicine delivery systems in-conjunction with physicians whose expertise
span cancer, obesity-&-diabetes, macular disease, infectious disease and traditional (Chinese) medicine.
Alicia Rebman – Marketing Director
Ms. Rebman is a Marketing professional with a background in Publishing Technologies, Communications, and Graphic Design;
specialty in branding/communications for social enterprise and NGO start-ups. Ms. Rebman ran a successful design services
company for six years and afterwards headed the marketing department for the Global office of Hartley & Marks Group, an
international design & publishing company.CSE: PREV
TEAM
OTCQB: PRVCF
Susan Blond - Director of Publicity
Appendix Susan Blond started her career painting with The Whitney Museum studio program but once she got a job at Andy Warhol’s
Interview, life was too exciting to paint. She sold ads there primarily to record companies and the magazine took off. She then
went on to United Artists and Epic/CBS Records where she became the first woman VP in the whole industry. The artists she
represented were Michael Jackson, Boy George, Sade, The Clash and countless others. She formed Susan Blond Inc in 1986 where
she not only represented Usher, The Spice Girls, and Morrissey, but companies such as The Hard Rock Cafe, Sports Club LA (now
Equinox) and executives like Charles Koppelman and Clive Davis. Susan serves as Secretary of the Board of DIFFA: Design
Industries Foundation Fighting AIDS.
Deanna Kress – Director of Communications and Investor Relations
Ms. Deanna Kress has been involved in public capital markets since 2003 with a focus on Investor Relations and Corporate
Communications. Ms. Kress has wide-ranging experience with a number of exploration and production companies listed on both
the TSX Venture Exchange and the Toronto Stock Exchange. Ms. Kress led various marketing initiatives with public and private
company management teams to assist with equity financing's, to secure coverage from all sectors of the investing community, and
to implement internal procedures to ensure clear and effective communication to stakeholders. Ms. Kress holds a Medical
Assistant Diploma and is in the process of completing a Health Sciences Degree.
Sydney Cole - Executive Assistant and Office Manager
Ms. Cole has held Administration Support and trainer roles within the Hospitality Industry for seven years. Ms. Cole has also
worked for a Venture Capital company for five years as an executive assistant and office manager. From bookkeeping to event
coordination Ms. Cole’s organisation and fortitude keep operations running smoothly.CSE: PREV
NON-ADDICTIVE ANALGESICS
OTCQB: PRVCF
Developing a novel class of painkillers that are derived from highly potent
Appendix painkilling molecules produced naturally, by the human body known as
‘dynorphin’.
The opioid epidemic is now associated with more deaths per year than motor
vehicle accidents and the prevalence of addiction is taxing public healthcare
systems and impacting social and economic welfare.
The research program commenced mid-2018, and is being led by PreveCeutical’s
Chief Research Officer, Dr. Harendra Parekh, in collaboration with the UQ School
of Pharmacy’s pain and inflammation pharmacology expert, Associate Professor
Peter Cabot.
Result filing of two new patent applications:
1. Australian Patent Application No. AU2019/900226, entitled “A Cyclic Peptide” filed January 24, 2019; and,
2. Australian Patent Application No. AU2019/900292, entitled “A Cyclic Peptide” filed January 30, 2019.CSE: PREV
NATURE IDENTICAL™
OTCQB: PRVCF
PreveCeutical’s research team is using proprietary chemistry to generate Nature
Appendix Identical™ peptides from the Caribbean Blue scorpion to assist with a range of
ailments from pain and arthritis, to the treatment of aggressive (brain) cancers.
Through preliminary screening in a glioblastoma (aggressive brain cancer) cell-
based assay, PreveCeutical’s research team has successfully identified four lead
peptides that inhibit the activity of a target protein implicit in the progression of
certain glioblastomas.
Next steps:
The program is ongoing, results from additional screening will be helpful in
determining further applications of research generated from the Peptide
Program.You can also read
